在患有特应性皮炎的狗中长期使用 lokivetmab。

IF 1.9 3区 农林科学 Q3 DERMATOLOGY
Veterinary dermatology Pub Date : 2024-12-01 Epub Date: 2024-08-14 DOI:10.1111/vde.13286
Bettina Kasper, Yury Zablotski, Ralf S Mueller
{"title":"在患有特应性皮炎的狗中长期使用 lokivetmab。","authors":"Bettina Kasper, Yury Zablotski, Ralf S Mueller","doi":"10.1111/vde.13286","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Lokivetmab, a caninised monoclonal antibody against interleukin (IL)-31, is an effective treatment for the pruritus associated with canine atopic dermatitis (cAD).</p><p><strong>Objectives: </strong>To investigate the efficacy and safety of lokivetmab during long-term treatment defined as at least three consecutive lokivetmab injections in atopic dogs under field conditions. To assess individual factors influencing treatment outcome and adverse events.</p><p><strong>Animals: </strong>150 dogs with cAD.</p><p><strong>Materials and methods: </strong>Medical records of dogs treated with lokivetmab were reviewed, and owners and/or veterinarians were contacted as needed for follow-up. A decrease of the pruritus Visual Analog Scale (PVAS) score by ≥2 or a PVAS score ≤2 after treatment was considered as treatment success. Logistic regression was used to investigate the influence of a variety of factors on outcome: type of cAD (food versus environment), age at first lokivetmab administration, disease chronicity, dosage and/or secondary infection. Any adverse event that occurred during the study period was recorded.</p><p><strong>Results: </strong>Lokivetmab reduced the PVAS score with long-term use (p < 0.01); the success rate was 53 of 69 total dogs (77%). The probability of treatment failure decreased with increasing treatment duration. None of the factors investigated influenced the treatment outcome. Twelve dogs of 150 (8%) showed adverse events such as gastrointestinal signs or lethargy.</p><p><strong>Conclusion and clinical relevance: </strong>Lokivetmab appears to be an effective and safe long-term anti-itch therapy for dogs with cAD.</p>","PeriodicalId":23599,"journal":{"name":"Veterinary dermatology","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Long-term use of lokivetmab in dogs with atopic dermatitis.\",\"authors\":\"Bettina Kasper, Yury Zablotski, Ralf S Mueller\",\"doi\":\"10.1111/vde.13286\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Lokivetmab, a caninised monoclonal antibody against interleukin (IL)-31, is an effective treatment for the pruritus associated with canine atopic dermatitis (cAD).</p><p><strong>Objectives: </strong>To investigate the efficacy and safety of lokivetmab during long-term treatment defined as at least three consecutive lokivetmab injections in atopic dogs under field conditions. To assess individual factors influencing treatment outcome and adverse events.</p><p><strong>Animals: </strong>150 dogs with cAD.</p><p><strong>Materials and methods: </strong>Medical records of dogs treated with lokivetmab were reviewed, and owners and/or veterinarians were contacted as needed for follow-up. A decrease of the pruritus Visual Analog Scale (PVAS) score by ≥2 or a PVAS score ≤2 after treatment was considered as treatment success. Logistic regression was used to investigate the influence of a variety of factors on outcome: type of cAD (food versus environment), age at first lokivetmab administration, disease chronicity, dosage and/or secondary infection. Any adverse event that occurred during the study period was recorded.</p><p><strong>Results: </strong>Lokivetmab reduced the PVAS score with long-term use (p < 0.01); the success rate was 53 of 69 total dogs (77%). The probability of treatment failure decreased with increasing treatment duration. None of the factors investigated influenced the treatment outcome. Twelve dogs of 150 (8%) showed adverse events such as gastrointestinal signs or lethargy.</p><p><strong>Conclusion and clinical relevance: </strong>Lokivetmab appears to be an effective and safe long-term anti-itch therapy for dogs with cAD.</p>\",\"PeriodicalId\":23599,\"journal\":{\"name\":\"Veterinary dermatology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2024-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Veterinary dermatology\",\"FirstCategoryId\":\"97\",\"ListUrlMain\":\"https://doi.org/10.1111/vde.13286\",\"RegionNum\":3,\"RegionCategory\":\"农林科学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/8/14 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Veterinary dermatology","FirstCategoryId":"97","ListUrlMain":"https://doi.org/10.1111/vde.13286","RegionNum":3,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/14 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:Lokivetmab是一种针对白细胞介素(IL)-31的犬化单克隆抗体,可有效治疗与犬特应性皮炎(cAD)相关的瘙痒症:研究在野外条件下对特应性皮炎犬至少连续注射三次 lokivetmab 的长期治疗过程中,lokivetmab 的有效性和安全性。评估影响治疗结果和不良事件的个体因素。动物:150 只患有 cAD 的狗:对接受过洛基韦单抗治疗的狗的医疗记录进行审查,并根据需要联系狗的主人和/或兽医进行随访。治疗后瘙痒视觉模拟量表(PVAS)评分下降≥2分或PVAS评分≤2分视为治疗成功。逻辑回归用于研究各种因素对治疗结果的影响:cAD类型(食物与环境)、首次使用lokivetmab的年龄、疾病慢性化程度、剂量和/或继发感染。研究期间发生的任何不良事件都会被记录在案:结果:长期使用 Lokivetmab 可降低 PVAS 评分(p 结论和临床意义:Lokivetmab似乎是一种针对cAD犬的有效、安全的长期止痒疗法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Long-term use of lokivetmab in dogs with atopic dermatitis.

Background: Lokivetmab, a caninised monoclonal antibody against interleukin (IL)-31, is an effective treatment for the pruritus associated with canine atopic dermatitis (cAD).

Objectives: To investigate the efficacy and safety of lokivetmab during long-term treatment defined as at least three consecutive lokivetmab injections in atopic dogs under field conditions. To assess individual factors influencing treatment outcome and adverse events.

Animals: 150 dogs with cAD.

Materials and methods: Medical records of dogs treated with lokivetmab were reviewed, and owners and/or veterinarians were contacted as needed for follow-up. A decrease of the pruritus Visual Analog Scale (PVAS) score by ≥2 or a PVAS score ≤2 after treatment was considered as treatment success. Logistic regression was used to investigate the influence of a variety of factors on outcome: type of cAD (food versus environment), age at first lokivetmab administration, disease chronicity, dosage and/or secondary infection. Any adverse event that occurred during the study period was recorded.

Results: Lokivetmab reduced the PVAS score with long-term use (p < 0.01); the success rate was 53 of 69 total dogs (77%). The probability of treatment failure decreased with increasing treatment duration. None of the factors investigated influenced the treatment outcome. Twelve dogs of 150 (8%) showed adverse events such as gastrointestinal signs or lethargy.

Conclusion and clinical relevance: Lokivetmab appears to be an effective and safe long-term anti-itch therapy for dogs with cAD.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Veterinary dermatology
Veterinary dermatology 农林科学-兽医学
CiteScore
3.20
自引率
21.40%
发文量
92
审稿时长
12-24 weeks
期刊介绍: Veterinary Dermatology is a bi-monthly, peer-reviewed, international journal which publishes papers on all aspects of the skin of mammals, birds, reptiles, amphibians and fish. Scientific research papers, clinical case reports and reviews covering the following aspects of dermatology will be considered for publication: -Skin structure (anatomy, histology, ultrastructure) -Skin function (physiology, biochemistry, pharmacology, immunology, genetics) -Skin microbiology and parasitology -Dermatopathology -Pathogenesis, diagnosis and treatment of skin diseases -New disease entities
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信